UbiVac Announces Preliminary Immunological Data from 1st-In-Human Trial of DPV-001 Immunotherapy Trio for Advanced HNSCC Bernie FoxFebruary 1, 2024
FDA Grants Approval for UbiVac Manufactured Coronavirus Vaccine to Start Clinical Trial Bernie FoxOctober 29, 2020
Dr Bernard Fox Joins CCFDIE Immunotherapy Workshop to Talk UbiVac's Combination Immunotherapy for Advanced Breast Cancer Bernie FoxOctober 18, 2020
Immuno-Oncology Pioneer Dr. Jon M. Wigginton Joins UbiVac’s Board of Directors Bernie FoxOctober 18, 2020
Triplet Immunotherapy for Metastatic Triple Negative Breast Cancer Presented at Chinese Society for Clinical Oncology Bernie FoxSeptember 24, 2020
UbiVac Announces Clinical Trial Collaboration with Bristol Myers Squibb on Combination Immunotherapy for Advanced Triple Negative Breast Cancer Bernie FoxJune 9, 2020
UbiVac Presents Personalized Cancer Vaccine Strategy at Cambridge Healthtech Institutes 6th Annual Immuno-Oncology Summit Bernie FoxOctober 17, 2018
Portland-Based Immuno-oncology Expert Dr. Bernard A. Fox To Present at NobleCon’s 14th Annual Investor Conference Bernie FoxOctober 16, 2018
Portland-Based Immuno-oncology Expert Dr. Bernard A. Fox To Present at Siena, Italy Conference Bernie FoxJune 11, 2018
UbiVac CEO to address FDA/AACR Workshop on Oncology Dosing and participate in Congressional Briefing Bernie FoxJune 11, 2018
Portland’s UbiVac To Detail Progress With New Cancer Therapy at International Immuno-Oncology Forum in New York Bernie FoxJune 11, 2018
UbiVac Releases New Lung Cancer Research Data: DPV-001 Vaccine Can Improve Treatment Response Rates Bernie FoxJune 11, 2018
Dr. Bernard A Fox enters March with bi-coastal speaking engagements for cancer research Bernie FoxJune 7, 2018
Immunotherapy Research Scientist Dr. Bernard Fox Receives International Award for Advancing Innovative Treatments to Cure Cancer Bernie FoxJune 7, 2018